Search the collection

3 results for Kreuzer,+Karl-Anton,+Prof

Sort by:

Sort by

Limit results to:

20 per page

3 results for Kreuzer,+Karl-Anton,+Prof

Export to excel

Export record to excel

File type to download

Beta version

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, ope...
Author / Creator:Eichhorst, Barbara, Dr ; Fink, Anna-Maria, MD ; Bahlo, Jasmin, PhD ; Busch, Raymonde, Dipl Math ; Kovacs, Gabor, MD ; Maurer, Christian, MD ; Lange, Elisabeth, MD ; Köppler, Hubert, Prof ; Kiehl, Michael, Prof ; Sökler, Martin, MD ; Schlag, Rudolf, MD ; Vehling-Kaiser, Ursula, MD ; Köchling, Georg, MD ; Plöger, Christoph, MD ; Gregor, Michael, MD ; Plesner, Torben, MD ; Trneny, Marek, Prof ; Fischer, Kirsten, MD ; Döhner, Harmut, Prof ; Kneba, Michael, Prof ; Wendtner, Clemens-Martin, Prof ; Klapper, Wolfram, Prof ; Kreuzer, Karl-Anton, Prof ; Stilgenbauer, Stephan, Prof ; Böttcher, Sebastian, MD ; Hallek, Michael, Prof
Publisher:England: Elsevier Ltd
Journal title:The lancet oncology, 2016-07, Vol.17 (7), p.928-942
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
Author / Creator:Cramer, Paula, MD ; von Tresckow, Julia, MD ; Bahlo, Jasmin, PhD ; Robrecht, Sandra, PhD ; Langerbeins, Petra, MD ; Al-Sawaf, Othman, MD ; Engelke, Anja, MD ; Fink, Anna-Maria, MD ; Fischer, Kirsten, MD ; Tausch, Eugen, MD ; Seiler, Till, MD ; Fischer von Weikersthal, Ludwig, MD ; Hebart, Holger, Prof ; Kreuzer, Karl-Anton, Prof ; Böttcher, Sebastian, MD ; Ritgen, Matthias, MD ; Kneba, Michael, Prof ; Wendtner, Clemens-Martin, Prof ; Stilgenbauer, Stephan, Prof ; Eichhorst, Barbara, MD ; Hallek, Michael, Prof
Publisher:England: Elsevier Ltd
Journal title:The lancet oncology, 2018-09, Vol.19 (9), p.1215-1228
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Author / Creator:Garcia-Manero, Guillermo, Dr Prof ; Fenaux, Pierre, Prof ; Al-Kali, Aref, MD ; Baer, Maria R, Prof ; Sekeres, Mikkael A, Prof ; Roboz, Gail J, Prof ; Gaidano, Gianluca, Prof ; Scott, Bart L, MD ; Greenberg, Peter, Prof ; Platzbecker, Uwe, Prof ; Steensma, David P, MD ; Kambhampati, Suman, MD ; Kreuzer, Karl-Anton, Prof ; Godley, Lucy A, Prof ; Atallah, Ehab, MD ; Collins, Robert, Prof ; Kantarjian, Hagop, Prof ; Jabbour, Elias, MD ; Wilhelm, Francois E, MD ; Azarnia, Nozar, PhD ; Silverman, Lewis R, MD
Publisher:England: Elsevier Ltd
Journal title:The lancet oncology, 2016-04, Vol.17 (4), p.496-508
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Export record to excel

Export this record

Export record to excel

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, ope...

Export this record

Export record to excel

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Export this record

Export record to excel

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Refine your search